You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.


Cancer Type: Genitourinary, Prostate      Intent: Palliative
Regimen Category: Evidence-Informed
Drugs Used:
abiraterone (Unfunded),
Exceptional Access Program
    abiraterone - Metastatic castrate-resistant prostate cancer, according to specific criteria
ODB - General Benefit

You might also be interested in